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Abstract
Background: Evaluation of decision-making capacity to consent to medical treatment has proved to be difficult in
patients with dementia. Studies showed that physicians are often insufficiently trained in the evaluation of decision-
making capacity. In this study, we present findings from a secondary analysis of a qualitative interviews with
physicians. These interviews were initially used to assess usability of an instrument for the evaluation of decision-
making capacity. By looking at difficult cases of decision-making capacity evaluation in patients with dementia, we
provide recommendations for such evaluations in clinical practice.
Methods: We used thematic coding to analyse physicians’ narratives of problematic decision-making capacity
evaluations in patients with dementia to uncover challenging issues of decision-making capacity evaluation.
Results: In this study, decision-making capacity evaluations in patients with dementia were mainly perceived as
challenging when they pertained to treatment refusals and treatment unrelated circumstances, such as psychiatric
consultation, advance directives, and new living arrangements. Furthermore, the physicians reported training needs
regarding situation-independent challenges with decision-making capacity evaluation.
Conclusions: Upon further examining self-reported training needs and challenging cases, we have developed
recommendations to improve decision-making capacity evaluations in clinical practice. In these recommendations,
we argue that being able to evaluate decision-making capacity is an integral part of the informed consent process.
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Background
Physicians have a legal and moral duty to obtain in-
formed consent from their patients for medical treat-
ment [1]. For a consent to be legally valid, the patient
must be informed thoroughly, make a voluntary choice,
and have decision-making capacity (henceforth DMC
[2]). As a prerequisite to valid consent, DMC has
become an indispensable pillar of modern patient-
centred medicine. However, the clinical evaluation of
DMC is difficult, especially in patients with dementia
[3–5]. In dementia, cognitive impairments often limit
the ability to understand, retain, and weigh different
treatment options [6, 7]. For example, cognitive fluctua-
tions are a recognised challenge to DMC evaluation [8].
Although cognitive fluctuations occur more often in
cases of dementia with Lewy bodies, where it is a distinct
diagnostic criterion, fluctuations in attention and mem-
ory are widely prevalent in all forms of dementia [9, 10].
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Nevertheless, it has been acknowledged that being diag-
nosed with dementia does not render a patient incompe-
tent per se [11–13].
Dementia is a common condition in the elderly popu-
lation, and in light of demographic changes, it is of par-
ticular clinical importance. The World Alzheimer
Report [14] estimated that the number of people affected
by dementia will double every 20 years, that is, by 2040
over 80 million people will be affected by dementia [15].
As a result, DMC evaluation of patients with dementia
will become an even more frequent concern for physi-
cians. In light of this, it is important that the physicians
are properly trained to evaluate DMC. However, a recent
scoping review of the literature found that training of
physicians on DMC and its evaluation is suboptimal
[16]. In focus group interviews with physicians, the same
study delved into major barriers with regard to the
evaluation of DMC, including, in particular, inconsist-
ency in approaches to DMC evaluation, and lack of
knowledge about the potential ethical tension between
patient autonomy and patient protection.
While theoretical aspects of DMC and instruments/
tools for its evaluation have been widely researched (e.g.
[17–19]), studies focusing on the actual DMC evaluation
in clinical practice are rare [20].
Aim of the study
In the present study, we explored how physicians actu-
ally carry out DMC evaluations and what issues they
perceive as challenging. In a secondary analysis of quali-
tative data from an interview study with physicians, we
extracted difficult cases of DMC evaluations with pa-
tients with dementia from physicians’ everyday practice
as well as the physicians’ self-reported training needs.
This provided the basis for the discussion of challenging
feature and general recommendations for physicians.
Methods
The present study is based on qualitative interviews
which were part of a nationwide research project on
DMC in Switzerland funded by the Swiss National Sci-
ence Foundation (SNSF) (for details, see [21]). As part of
this project, an evaluation instrument was developed to
account not only for abilities of the patient, but to also
capture physician-associated factors (e.g., intuitions,
value judgements) in the decision-making process (for
details, see [22–24]). The interviews were part of an
evaluation of usability and feasibility of this instrument.
As confirmed by the cantonal ethics commission of Zur-
ich, Switzerland, in January 2015 in accordance with the
Swiss Human Research Act, ethical review by the can-
tonal ethics commission was not required because no
health-related personal data from the assessed physicians
has been gathered in the present study. Written
informed consent was not necessary. However, all partic-
ipants consented verbally to participate.
Participants
A total of 24 healthcare professionals took part in the
project of which 18 study participants were physicians.
These initial participants were sampled by convenience.
For the present study, we focused on the perspectives of
the physicians as they are often legally responsible for
the evaluation of DMC as attending physicians. We ex-
cluded the five nurses and one psychologist from the
analysis. The physicians worked in internal medicine
(n = 10), in psychiatry or psychiatric consultation (n = 6),
or in other specialties (n = 2).
Qualitative data
All study participants received two-hour training on the
concept and evaluation of DMC, for which they received
six credits by the Swiss Institute for Advanced Medical
Training and Education. In the subsequent four-month
period, participants were asked if evaluation of DMC
was an issue in their clinical practice, to use the newly
developed DMC evaluation instrument to evaluate the
patient’s DMC. After 4 months, face-to-face semi-
structured interviews were conducted (see [21]). The
main aim of the interviews was to assess qualitatively the
feasibility and usability of the instrument in everyday
clinical practice. Study participants were also asked
about difficulties in evaluating DMC and about their
perceived training needs in the evaluation of DMC. Fur-
thermore, participants were asked to report cases from
their experience during the last 4 months where the pa-
tient’s DMC was questionable. The interview language
was Swiss German and interviews were conducted be-
tween April and November 2016. All interviews took
place at the workplace of the study participant (e.g. hos-
pital, general practice), during which only the inter-
viewer and the interviewee were present. The mean
length of the interviews was 45 min. Interviews were
audio recorded and transcribed verbatim into written
German.
Data analysis
The secondary analysis of the interview data firstly fo-
cused descriptively on the difficulties study participants
reported when evaluating DMC in patients with demen-
tia. To be within this category, it was necessary that (a)
the patients who were discussed by the participants had
a diagnosis of dementia, and (b) that the physician par-
ticipants reported that they had significant problems in
evaluating DMC in these patients. Of the 26 patient
cases discussed by the 18 participants, 9 physicians dis-
cussed 11 cases fulfilling these conditions. Secondly, the
answers of the same study participants with regard to
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their own training needs were aggregated (5 out of 9).
Thirdly, the resulting data set for this paper from the
above two procedures was inductively analysed with the-
matic analysis [25] to further understand the needs in
dementia-related DMC evaluation.
One author (CP) carried out the data extractions and
aggregations. All co-authors read the extracted data and
discussed ethical and medical themes inherent in the
physicians’ case narratives, which were grouped into
three prevailing themes: (1) treatment refusals, (2) treat-
ment unrelated circumstances, and (3) situation-
independent challenges of DMC evaluation.
Findings
In this section, the clinical situations corresponding to
the themes and which made DMC evaluation challen-
ging are presented. In the next section, the ethically and
medically challenging issues inherent in the aforemen-
tioned evaluation of DMC in patients with dementia are
discussed. Moreover, we provide recommendations for
challenging issues in the evaluation of DMC.
Clinical situations that challenge evaluation of DMC
Theme 1: when patients with dementia refuse treatment
In three of the reported challenging cases (cases 1, 6,
and 8), participants described patients who refused treat-
ment even though severe medical risk was involved in
not having the treatment. In all cases, the refusal was
respected by the responsible physician despite the ab-
sence of the patient’s DMC.
Case 1: An elderly patient with severe dementia re-
fused to undergo surgery for her malignant tumour. In
addition, her dementia had deteriorated before refusing
to undergo surgery. The tumour was likely to grow and
there was a high risk of tumour related infection. In earl-
ier oral statements, she had also expressed her refusal of
surgery. The attending physicians deemed her to lack
DMC to refuse treatment. However, her daughter was
present and stressed the importance to respect her wish.
In the end, the physicians did not conduct the surgery.
Case 6: A patient of old age with mild dementia re-
fused follow-up chemotherapy after tumour surgery.
The physician had to inform the patient repeatedly
about the risks and benefits as she had forgotten the
relevant information after each appointment. The pa-
tient’s reason for deciding against the chemotherapy was
that it would lead to hair loss. At each appointment, the
decision not to undergo chemotherapy was consistent
and she was deemed capable of decision-making.
Case 8: An elderly patient refused a surgical amputa-
tion of his gangrenous leg. As it is discussed further
below, the patient underwent psychiatric consultation
and was evaluated to lack DMC. In this case, there was
no family member present, nor were there any advance
oral statements or written directives and the refusal im-
plied severe medical risk including death from septicae-
mia. Nonetheless, the physicians respected the patient’s
wish which led to his death.
Theme 2: treatment-unrelated circumstances
DMC evaluations were not only found to be complicated
by apparently risky treatment refusal but were reported
as difficult by the study participants in several situations
such as when psychiatrists had to be involved in the
DMC evaluation process, DMC in the context of ad-
vance directives (AD), and DMC when patients wanted
to decide further care or living arrangements.
Psychiatric consultation In two of our cases (cases 2
and 8), the attending physician asked for psychiatric
consultation to assist with DMC evaluation. In both
cases the attending physician did not formally evaluate
DMC and the psychiatrist declared the patient not to
have DMC to make decisions. Despite this conclusion
from the psychiatrist, the attending physician did not
recommend the patient to undergo the indicated treat-
ment procedure, notwithstanding apparently negative
consequences for the patient if they did not have the
treatment (i.e., death of the patient in case 8).
Advance directives When writing an advance directive,
DMC has to be evaluated if there is reasonable doubt
that the patient might lack DMC as the advance direct-
ive is only valid if developed by a competent patient.
Nevertheless, in most legal systems every adult person is
presumed to have DMC (e.g., Swiss Civil Code 2018,
Art. 16; UK: Mental Capacity Act 2005, section 1, 2nd
principle). In Switzerland, advance directives are binding
by law, but need not satisfy specific formal requirements.
In advance directives, a legal guardian can be appointed.
If there is no advance directive, there is cascade of
guardianship among the closest family members and
relatives.
In case 4, the patient was deemed unable to write an
advance directive as he did not have the DMC to under-
stand what was discussed. In this case, legal authorities
became involved and a family member was appointed as
his guardian. In case 10, the physician had doubts about
the patient’s DMC, but the advance directive was still
written due to the presence of the family who confirmed
the patient’s wishes which helped the physician to con-
clude that the patient was competent (no further details
could be extracted from the data). In case 3, a patient
with moderate dementia had prepared an advance dir-
ective with a notary, in which her son was appointed as
the primary guardian. She then accused her son of steal-
ing her money. The physician could neither evaluate
DMC retrospectively nor decide whether the patient had
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been capable of writing the advance directive. The phys-
ician could not certify the irrationality of the assertion
that the patient’s son was stealing. The case was subse-
quently transferred to the respective legal authorities
(i.e. child and adult protective services).
New living arrangements Furthermore, DMC is often
in question when new living and care arrangements for
elderly patients with dementia are discussed. In case 5,
an older man with dementia who had a wakened night
shift wanted to leave the hospital. The physicians
doubted whether he was able to care for himself at
home. Two cases (cases 7 and 9) deal with patients with
dementia whose circumstances were such that family
members or healthcare professionals who were unable
to provide the needed care at home and urged these pa-
tients to move into nursing homes. In these cases, physi-
cians either let the patient go home under surveillance
(case 5), persuaded or informed the patients repeatedly
about the need to go into a nursing home (both case 7
and 9).
Theme 3: situation-independent challenges in decision-
making capacity evaluation
Several of the study participants reported having had dif-
ficulties with different legal issues related to DMC evalu-
ation. One study participant reflected:
So, I wouldn’t have known for example, or at least I
wouldn’t have known it directly, that this [lack of
DMC] is not required when ordering involuntary
admission1 (mhm), hence I believe that there could
be a lack of information. – Interviewee 17 (case 9).
Not knowing involuntary admission is independent of
a person’s DMC is an example of lack of legal knowledge
in the context of DMC evaluations, but this is not spe-
cific to dementia. For example, physicians found it diffi-
cult to evaluate DMC when the patient was subject to a
guardianship order or had instated a lasting power of at-
torney. One participant noted that in her, falsely held,
view the law might contradict itself in these cases:
I question if it is necessary for a full guardianship
that the patient does not have DMC. Children and
adult protection law formulate it this way.2 This
bothers me. DMC is always dependent on a certain
situation and you cannot generally declare someone
as not having DMC per se and put a guardianship
in place. — Interviewee 2 (case 2).
Apart from uncertainty about the law with regard to
DMC, the clinical evaluation of DMC was a concern for
the study participants. However, a variety of instruments
exist to evaluate DMC, e.g. the MacCAT-T [26]. One
physician expressed the wish for accessible screening in-
struments in DMC evaluations:
So, I think that would be a good thing, I mean, we
now work a lot with scores and such on the derma
[dermatological station] to assess the severity and it
is easy, and you can get training then […] sure, that
training [on DMC] would be more complex and
one would have to train with cases, as we did in the
training session. – Interviewee 8 (case 7).
In reports about clinical evaluation of DMC, several
study participants emphasised the need for economical,
reliable screening instruments. Another physician stated
that
it would be wonderful if there were any question-
naire with scores. I am working in assessment. I am
asking 10 questions. If the patient has a score of 4,
he has a depression. It would be nice if this existed
[for DMC]. But I, too, don’t see how. – Interviewee
1 (case 1).
In general, the role cognitive screening instruments
play in DMC evaluation is reported to be unclear, for ex-
ample, whether a cut-off score can be an indicator of
lack of DMC. In one case (case 4), cognitive testing
alone was used to evaluate DMC.
Discussion: challenging issues raised when
evaluating decision-making capacity of patients
with dementia
A patient with dementia refuses treatment
In all clinical cases, treatment refusal was respected. No
patient was forced into undergoing treatment. In prac-
tice, there could be a different threshold applied for re-
fusal than for consent to treatment. Furthermore,
consequences of not respecting refusal might also be
graver than respecting it. This is in line with the legal
“right to refuse” life-prolonging treatment [27] of com-
petent patients. However, a prerequisite for the refusal is
that the patient is able to make a considered decision.
When the patient lacks DMC, physicians are morally
obliged to promote the welfare of their patients. In
1In Switzerland, under Art. 426 of the Civil Code, involuntary
admission is possible independent of decision-making capacity. How-
ever, involuntary treatment of competent persons is not allowed.
2This is actually not the case in Switzerland. Permanent absence of
capacity will or could lead to full guardianship – the unofficial Swiss
translation uses General Deputyship, but full guardianship does not
necessarily mean permanent absence of capacity under Art. 398 of the
Swiss Civil Code.
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Table 1, challenging issues of the cases are presented in
which informed refusal was complicated by dementia.
A patient with dementia wants to write an advance
directive
The question of DMC arises in the context of advance
directives at different times. First of all, DMC is needed
at the time of writing an advance directive as well as
when changing it. Once a legally valid advance directive
is in place, it can be open to challenge in court if there
is reasonable doubt that the patient lacked DMC at the
time of writing the advance directive. In Table 2, chal-
lenging issues for DMC evaluations from the cases of
the present study are presented.
This result seems to emphasize the importance of ad-
vance care planning (ACP) in dementia, for example
through general practitioners [28]. However, ACP in de-
mentia is also challenging [29]. Indeed, the process of
ACP in dementia shares the general challenges of evalu-
ation of DMC outlined in this article, for example the
involvement of family caregivers and relatives [30].
Closely related to advance directives is the question
about what to do when a patient cannot be supported
and cared for at home any longer. Similarly, as with ad-
vance directives, the role of the family and DMC evalu-
ation presents a challenging issue.
A patient is unable to care for himself but wants to go
home
Care decisions are treatment unrelated but nonetheless
can considered as health decisions. As such, DMC is
often evaluated to decide upon alternative care arrange-
ments when the needed care cannot be provided by in-
formal caregivers at home or outpatient nursing
teams (see Table 3). These cases often need a multi-
professional team effort, involving physicians and social
workers alike.
Physicians encounter these challenging issues by find-
ing a solution to minimise risk and maximise medical
benefit. This has often little to do with a formal DMC
approach. Physicians negotiate and try to get acceptance
of patients for their transfer to a nursing home.
Conclusion: recommendations to address
decision-making capacity evaluations of patients
with dementia
Evaluation of decision-making capacity as part of the
informed consent process
We recommend DMC evaluation as part of a nuanced
informed consent or informed refusal process [31]. A
formal DMC evaluation becomes necessary if there is
reasonable doubt that the patient might lack DMC, e.g.
in the case of a patient with a diagnosis of dementia. Fo-
cussing on informed consent ensures that first all rea-
sonable steps have to be taken to provide the necessary
information for the patient to decide. For example, the
importance of informing the patient in a thorough and
easy comprehensible manner should not be underesti-
mated [1].
Furthermore, the physician should assess and ask the
family when and where the patient is cognitively at their
best, e.g. if the patient experiences confusion later in the
day (‘sundowning’). If there is temporary fluctuation in
attention and memory [8] the informed consent process
should be repeated at least two different times before a
final decision is made [32]. If sufficient information is
provided and the patient still seems unable to coherently
consent or refuse treatment, the physician’s clinical
judgement is needed about whether or not the patient
has the DMC to make decisions.
We agree that this judgement is subjective [11, 22] in
the sense that the physician’s values, observations, and
own experiences may influence it. It is suggested that
physicians discuss these cases in case conferences and
Table 1 Treatment refusal in cases of dementia
Refusal Challenging issue
Minor intervention with a low or unclear risk involved where
the patient has no living relatives or legal representatives.
Mild forgetfulness: Information about the intervention is lost after each
appointment, but the attention and awareness are preserved so that
momentary informed consent is possible.
Intervention for major, but non-life-threatening disease. Severe cognitive deficits, but earlier oral statements consistent with the refusal.
Life-saving surgery (e.g., necessary amputation) and the patient
has no living relatives or next of kin.
Patient lacks capacity according to the psychiatric consultant, but to neglect
the refusal would mean to heavily infringe on the patient’s actual expressed will.
Table 2 Issues with advance directives
Status of advance directive Challenging issue
The patient has set up an advance directive already.
The patient now wants to change the primary care taker enlisted in
the advance directive.
Capacity is in doubt and no thorough formal evaluation at the time of the
writing of the advance directive is available.
The patient wants to set up an advance directive in the presence of
the family.
The presence of and support for the advance directive by the family might
suggest that a formal capacity evaluation is not required.
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supervision sessions. This clinical judgement can also be
informed by a psychiatric consultation in some cases.
Psychiatric evaluation of decision-making capacity
It has been called a myth of DMC that only a psych-
iatrist can evaluate DMC [33]. In cases where dementia
is related to, or concomitantly present together with, se-
vere mental disorder, psychiatric consultation is advis-
able. Nevertheless, DMC evaluations by psychiatric
consultants are not overruling the clinical judgement of
the treating physician, who retains legal responsibility
for the evaluation. In addition, the attending physician
(in general) is most informed of risks and benefits of the
decision at hand, has known the patient the longest, and
can judge best the state the patient is in. In dementia,
the cognitive state of patients can also be assessed by
neurologists and neuropsychologists to inform the DMC
evaluation of the treating physician. If psychometric in-
struments such as the Mini-Mental-State-Exam (MMSE
[34]) are employed, these should only be used as a
decision-aid and not as stand-alone diagnostic tool for
the patient’s DMC. Even the use of low cut-off scores, as
is use for consent to research less than 10 of 30 in the
MMSE [35], runs the risk of neglecting patients with de-
mentia, who might have otherwise decided for them-
selves. Although psychometric instruments have an
important place in practice, they cannot substitute clin-
ical judgement. This clinical judgement can be sup-
ported by tools focusing on the process of DMC
evaluation (e.g. from the Swiss context, the U-Doc [24]).
Solution-focused decision-making while respecting the
right to autonomy
The use of solution-focused approaches if DMC is lack-
ing is common in multifaceted medical decisions. We
understand solution-focused approaches akin to a casu-
istic approach to decision-making based on human
rights [36]. This human rights approach is different to a
mental capacity/welfare-based approach because human
rights such as outlined in Article 5 and 8 ECHR are in-
dependent of DMC evaluations. One example might be
that “the detention of a person lacking DMC cannot be
justified simply on the basis that doing so is in their best
interests” [36].
Another example closer to our cases, a physician
might let a patient go home even though he considers
him incapable of decision-making. He might ask the pa-
tient to report back or ask family members to report
about the state of the patient’s health. This way, the pa-
tient’s right of autonomy is preserved but the physician’s
corresponding duty to protect the patient is served also.
Unclear at this point is what constitutes valid solution-
focused approaches based on human rights without in-
volving legal institutions. One key aspect might be good
patient-physician communication, which can convince
the patient of the need for further care without being pa-
ternalistic or controlling, hence infringing on the right
to autonomy [37]. Furthermore, in cases where the ap-
pointment of a guardian is not possible, it might become
necessary to involve social workers and the responsible
legal institutions, e.g. child and adult protective services
in the Swiss context. Using a right-based approach, the
legal institutions, e.g., will “consider the issue from the
perspective of each relevant party, explain their rights
and justify, where appropriate, the interference in their
rights” [36]. While solution-focused approaches do not
rely solely on formal DMC evaluations, in practice this
kind of decision making is of utmost importance.
Presence of relatives and the evaluation of decision-
making capacity
If the physician concludes that the patient cannot con-
sent, legal guardianship by family members or other rel-
atives is advisable. A right-based approach has the
unique advantage that it can balance conflicts between
family members and, as already pointed out, does not
simply overrule patient autonomy.
It is suggested that the guardianship or lasting power
of attorney is appointed by, for example a court of pro-
tection. This legal recognition serves as a safeguard for
family members. Furthermore, notwithstanding that the
patient lacks DMC, the patient’s preferences and wishes
should determine decision making as he still has a right
to autonomy. In establishing patients’ preferences, family
members can also serve as informants.
Conclusion
Medical and ethical aspects of right-based approaches in
clinical practice are a neglected field in decision-making
research. The involvement of family and relatives as
guardians demand closer attention in the context of de-
mentia. Further research should examine solution-
focused decision making in a clinical context.
Table 3 Capacity when care cannot be provided
Care situation Challenging issue
The patient is admitted to the hospital because care cannot be provided at home. The patient is unwilling to resettle into a nursing home.
The patient is unable to care for herself at home and was hospitalized several times before. The patient wants to stay at home.
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